Latest Regulatory Milestones News

Aguia Resources has enhanced its capital raising by increasing free attaching options to one per new share in its $4 million entitlement issue, now open to shareholders in Australia, New Zealand, and Hong Kong.

Meteoric Resources has obtained crucial environmental consent to operate within the sensitive buffer zone of the Serra da Pedra Branca sanctuary, clearing a major hurdle for its Caldeira Rare Earth Project in Brazil.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Locksley Resources has gained critical regulatory approval and secured contractors to advance its Mojave Project, accelerating exploration of antimony and rare earth elements in California.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

Global Uranium and Enrichment Limited reports promising drilling outcomes and regulatory progress at its Pine Ridge Uranium Project in Wyoming, reinforcing its potential amid a strengthening uranium market.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

Wia Gold Limited has completed a Scoping Study for its Kokoseb Gold Project in Namibia, confirming its potential as a long-life, economically viable open pit mine with strong financial metrics and a clear path to development.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Challenger Gold has secured the final Environmental Impact Assessment amendment for its Hualilán Gold Project, enabling ore haulage and toll milling at the Casposo plant. This milestone unlocks a low-capital pathway to early cash flow while advancing the project’s development.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.